血清镁对心力衰竭重症监护患者死亡率的影响:基于MIMIC-III数据库的回顾性分析
该回顾性队列研究基于MIMIC-III数据库,纳入2001至2012年贝斯以色列女执事医疗中心ICU收治的1162例心衰患者,按是否合并肾衰竭分为非肾衰竭组695例和肾衰竭组467例,90天全因死亡317例(27.3%)。多因素分析显示,调整混杂因素后肾衰竭组血清镁与死亡率无显著关联(OR=1.053,95%CI 0.519-2.132,P>0.05),非肾衰竭组血清镁显示保护效应(OR=0.460,95%CI 0.239-0.885,P<0.05)。交互分析显示非肾衰竭组BUN与血清镁存在交互作用(交互P<0.05),高BUN亚组血清镁与死亡率显著相关(OR=0.082,95%CI 0.016-0.406,P<0.05),低BUN亚组无显著关联(OR=0.946,95%CI 0.466-1.918,P>0.05);肾衰竭组BUN与血清镁无交互作用(交互P>0.05),高、低BUN亚组血清镁与死亡率均无显著关联(均P>0.05)。
要点
- 非肾衰竭心衰ICU患者中,调整混杂后血清镁升高与90天全因死亡率降低相关(OR=0.460,95%CI 0.239-0.885,P<0.05)。
- 非肾衰竭且高BUN亚组中,血清镁与死亡率显著相关(OR=0.082,95%CI 0.016-0.406,P<0.05),低BUN亚组无显著关联(OR=0.946,95%CI 0.466-1.918,P>0.05)。
- 肾衰竭心衰ICU患者中,调整混杂后血清镁与90天全因死亡率无显著关联(OR=1.053,95%CI 0.519-2.132,P>0.05),高、低BUN亚组均无显著关联(均P>0.05)。
- BUN与血清镁在非肾衰竭组存在交互作用(交互P<0.05),在肾衰竭组无交互作用(交互P>0.05)。
- 阈值效应分析识别血尿素氮拐点为530 mg/L,用于交互分析分层。
适用人群与场景
- 2001至2012年贝斯以色列女执事医疗中心ICU收治的心力衰竭患者,共1162例,其中非肾衰竭组695例、肾衰竭组467例。
诊断标准与关键阈值
- 根据是否合并肾衰竭分为非肾衰竭组与肾衰竭组。
- 阈值效应分析识别血尿素氮拐点为530 mg/L,据此进行高BUN与低BUN亚组分析。
研究设计与关键结果
- 研究类型为基于MIMIC-III数据库的回顾性队列研究,纳入1162例心衰ICU患者,非肾衰竭组695例、肾衰竭组467例,90天全因死亡317例(27.3%)。
- 单因素分析:肾衰竭组血清镁与死亡率显著相关(OR=1.994,95%CI 1.223-3.252,P<0.05),非肾衰竭组无显著关联(OR=1.098,95%CI 0.700-1.722,P>0.05)。
- 多因素分析:调整所有选定混杂因素后,肾衰竭组血清镁与死亡率无显著关联(OR=1.053,95%CI 0.519-2.132,P>0.05),非肾衰竭组血清镁显示保护效应(OR=0.460,95%CI 0.239-0.885,P<0.05)。
- 交互分析:非肾衰竭组BUN与血清镁存在交互作用(交互P<0.05),高BUN亚组血清镁与死亡率显著相关(OR=0.082,95%CI 0.016-0.406,P<0.05),低BUN亚组无显著关联(OR=0.946,95%CI 0.466-1.918,P>0.05);肾衰竭组BUN与血清镁无交互作用(交互P>0.05),高BUN与低BUN亚组血清镁与死亡率均无显著关联(均P>0.05)。
证据类型、等级与局限
- 证据类型:基于MIMIC-III数据库的回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,肾功能和BUN水平显著修饰心衰ICU患者血清镁与90天全因死亡率的关系:非肾衰竭高BUN患者死亡率随血清镁升高显著降低,非肾衰竭低BUN患者死亡率随血清镁浓度无显著变化,肾衰竭患者无论BUN水平如何死亡率随血清镁浓度无显著变化。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To analyze the effect of serum magnesium on 90-day all-cause mortality in heart failure patients admitted to the intensive care unit (ICU).
METHODS: A retrospective cohort study was conducted using data from the Medical Information Mart for Intensive Care- III (MIMIC- III) database. Heart failure patients admitted to the ICU of Beth Israel Deaconess Medical Center between 2001 and 2012 were selected. Demographic characteristics, comorbidities, initial vital signs, and laboratory data were extracted. The outcome measure was 90-day all-cause mortality after ICU admission. Patients were divided into non-renal failure and renal failure groups based on the presence of renal failure. Univariate Logistic regression was used to analyze the relationship between potential confounding factors and the 90-day all-cause mortality. Multivariate Logistic regression was used to analyze the independent effect of serum magnesium on the 90-day all-cause mortality. A threshold effect analysis identified an inflection point for blood urea nitrogen (BUN) at 530 mg/L, and an interaction analysis examined the effect of BUN on the relationship between serum magnesium and the 90-day all-cause mortality.
RESULTS: A total of 1 162 ICU patients with heart failure were included, among which 695 were in the non-renal failure group and 467 in the renal failure group; 317 patients died (27.3%). Univariate analysis showed that serum magnesium was significantly associated with mortality in the renal failure group [odds ratio (OR) = 1.994, 95% confidence interval (95%CI) was 1.223-3.252, P < 0.05], but not in the non-renal failure group (OR = 1.098, 95%CI was 0.700-1.722, P > 0.05). Multivariate analysis showed that after adjusting for all selected confounding factors, serum magnesium was not significantly associated with mortality in the renal failure group (OR = 1.053, 95%CI was 0.519-2.132, P > 0.05), while in the non-renal failure group, serum magnesium showed a protective effect (OR = 0.460, 95%CI was 0.239-0.885, P < 0.05). The interaction analysis between BUN and serum magnesium showed that after adjusting for all selected confounding factors, there was an interaction between BUN and serum magnesium in the non-renal failure group (interaction P values were < 0.05), with a significant association between serum magnesium and mortality in the high BUN subgroup (OR = 0.082, 95%CI was 0.016-0.406, P < 0.05), but no significant association in the low BUN subgroup (OR = 0.946, 95%CI was 0.466-1.918, P > 0.05); there was no interaction between BUN and serum magnesium in the renal failure group (interaction P values were > 0.05), and there was no significant association between serum magnesium and mortality in both the high BUN subgroup and the low BUN subgroup (all P > 0.05).
CONCLUSIONS: Renal function and BUN levels significantly modify the relationship between serum magnesium and 90-day all-cause mortality in heart failure patients admitted to the ICU. The mortality significantly decreases with the increase of serum magnesium in non-renal failure patients with high BUN, while the mortality shows no significant change with serum magnesium concentration in non-renal failure with low BUN. In renal failure patients, no significant change in mortality occurs with varying serum magnesium concentration, regardless of BUN levels.
参考来源
- Ma J, Zhang S, Hou Y, et al. [Effect of serum magnesium on mortality in intensive care unit patients with heart failure: a retrospective analysis based on the MIMIC-III database]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 41500689. doi:10.3760/cma.j.cn121430-20250122-00053
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。